

CONTENT

- OLD AND NEW IN LIPID LOWERING THERAPY: FOCUS ON THE EMERGING DRUGS 811
DANIELA BARTOȘ, CAMELIA DIACONU, ELISABETA BĂDILĂ, ANA MARIA DARABAN
- A BRIEF OVERVIEW ON COCRYSTALS AND THEIR PHARMACEUTICAL APPLICATIONS 824
MANOJ KUMAR SARANGI
- SQUALENE – NATURAL RESOURCES AND APPLICATIONS 840
IOANA POPA, NARCISA ELENA BĂBEANU, SULTANA NIȚĂ, OVIDIU POPA
- *IN VITRO* ESTROGENIC/ANTI-ESTROGENIC EFFECTS OF CERTAIN FOOD ADDITIVES AND COSMETIC PRESERVATIVES 863
ANCA POP, BELA KISS, TUDOR DRUGAN, JULIEN CHERFAN, FELICIA LOGHIN
- COMPARATIVE STUDY ON THE VOLATILES' COMPOSITION OF *IRIS DICHOTOMA* PALL. RHIZOME EXTRACTS 874
WIRGINIA KUKULA-KOCH, KRYSZYNA SKALICKA-WOŹNIAK, ELWIRA SIENIAWSKA, JAROSLAW WIDELSKI, OTGONBATAAR URJIN, PAWEŁ GŁOWNIAK
- THE SYNERGISTIC ANTINOCICEPTIVE INTERACTION OF CODEINE AND PREGABALIN IN A SOMATIC PAIN MODEL IN MICE 882
ELIZA GRAȚIELA POPA, LILIANA MITTELU TARTAU, RAOUL VASILE LUPUȘORU, CĂTĂLINA ELENA LUPUȘORU, IULIAN STOLERIU, LĂCRĂMIOARA OCHIUZ
- ARE SSRI'S EQUALLY SAFE IN PREGNANCY? FLUOXETINE AND CITALOPRAM EXPERIMENTAL STUDY 889
BIANCA EUGENIA ŐSZ, CAMIL EUGEN VARI, MELINDA KOLCSĂR, OVIDIU SIMION COTOI, MARIUS ȘTEFAN MĂRUȘTERI, MARIA T. DOGARU
- BETADINE® IN CHEMICAL PLEURODESIS 897
CLAUDIU NISTOR, AURELIAN-EMIL RANETTI, ADRIAN CIUCHE, DANIEL PANTILE, LAURA-MARIANA CONSTANTIN, ROXANA BRÎNCOVEANU
- ANTI-TUMOR EFFECT OF *EUONYMUS EUROPAEUS* ON EHRlich TUMOR CELLS *IN VIVO* 907
BOGDAN SEVASTRE, ORSOLYA SÁRPATAKI, NELI K. OLAH, ROXANA L. STAN, MARIAN TAULESCU, IOAN MARCUS, CORNEL CĂTOI
- SPECTRAL CHARACTERIZATION OF NEW 2-((4-ETHYLPHENOXY)METHYL)-N-(ARYLCARBAMOTHIOYL) BENZAMIDES 918
MIRON TEODOR CĂPROIU, CARMEN LIMBAN, ALEXANDRU VASILE MISSIR, DIANA CAMELIA NUȚĂ, LAURENȚIU MORUȘCIAG
- PHYTOBIOLOGICAL TESTING OF SOME COMPOUNDS WITH 4(3H) - QUINAZOLONE STRUCTURE 929
MIHAELA BRATU, OCTAVIAN TUDOREL OLARU, ILEANA CORNELIA CHIRIȚĂ, MIHAELA DINU, ADRIANA IULIANA ANGHEL
- THE IMPACT OF DIFFERENCES BETWEEN REGULATORY GUIDANCE FOR *IN VITRO* TESTING ON THE DISSOLUTION PROFILES OF MYCOPHENOLATE MOFETIL 942
NAHLA NUMAN AQEL, DUMITRU LUPULEASA, MIRELA ADRIANA MITU, ANA ANDREEA STĂNESCU, CĂTĂLIN DONEA, DALIA SIMONA MIRON, FLAVIAN ȘTEFAN RĂDULESCU
- THE LEVELS OF SERUM BIOMARKERS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 950
ANGELA ANTONESCU, SIMONA IOANA VICAS, ALIN C. TEUSDEA, IOANA RATIU, INA ANDREEA ANTONESCU, OTILIA MICLE, LAURA VICAS, MARIANA MURESAN, FELICIA GLIGOR
- RESEARCHES UPON INDIGENOUS HERBAL PRODUCTS FOR THERAPEUTIC VALORIFICATION IN METABOLIC DISEASES. NOTE II. POLYPHENOLS CONTENT, ANTIOXIDANT ACTIVITY AND CYTOPROTECTIVE EFFECT OF *BETULAE FOLIUM DRY EXTRACT* 961
TEODORA COSTEA, LAURIAN VLASE, VIORICA ISTUDOR, MARIA-LIDIA POPESCU, CERASELA-ELENA GÎRD
- STUDY ON THIAMPHENICOL – INDUCED SIDE EFFECTS IN HAMSTERS 971
MARIA CRIVINEANU, MANUELLA MILITARU, DENISA IOANA UDEANU, VALENTIN NICORESCU, CAMELIA PAPUC, CORINA ANA IONIȚĂ, ELENA ROTARU
- NICOTINE DETERMINATION FROM TABACCO BY GC/MS 982
DOINA ȘPAIUC, ADRIAN ȘPAC, LUMINIȚA AGOROAEI, ELENA BUTNARU
- PERCUTANEOUS PENETRATION ENHANCEMENT OF PROPRANOLOL HYDROCHLORIDE FROM HPMC-BASED HYDROETHANOLIC GELS CONTAINING TERPENES 991
LAVINIA VLAIA, IOANA OLARIU, GEORGETA CONEAC, VICENȚIU VLAIA, CĂLIN POPOIU, STĂNCIULESCU CORINA, ANA MARIA MUȚ, ZOLTAN SZABADAI, DUMITRU LUPULEASA
- PHARMACOKINETIC EVALUATION OF A NOVEL RUTHENIUM (III)-OFLOXACIN COMPLEX, AS POTENTIAL THERAPEUTIC AGENT 1009
BRUNO ȘTEFAN VELESCU, VALENTINA ANUȚĂ, VALENTINA UIVAROȘI
- RESEARCHES CONCERNING THE PROFITABILITY OF THE COMMUNITY PHARMACY WITHIN THE CONTEXT OF WORLD ECONOMIC AND FINANCIAL CRISIS 1025
ANAMARIA BOBOIA, GABRIELA CARMEN OROS, CONSTANTIN POLINICENCU, SIMONA MIREL
- THE STUDY OF PHARMACOPOLYMERAS USED IN THE ROMANIAN AREA IN XVIII-XXth CENTURIES: EVOLUTION OF PROPORTIONS FOR DRUG SUBSTANCES AND PHARMACEUTICAL PREPARATIONS 1037
EMILIA STANCU, ANA CARATA, ADRIANA-ELENA TĂEREL, VALENTINA SOROCEANU

✉ ssfr@revistafarmacia.ro
www.revistafarmacia.ro

ISSN 0014-8237

Romanian Society for Pharmaceutical Sciences

Farmacia

5

Volume 62
September - October 2014

EDITORIAL BOARD

Editor-in-Chief

Prof. Niculina MITREA-VASILESCU, PhD

Associate Editor-in-Chief

Prof. Ileana CHIRIȚĂ PhD

Managing Editors:

Prof. Adrian ANDRIEȘ, PhD

Prof. Camelia Elena STECOZA, PhD

Assoc. Prof. Andreea Letiția NIȚULESCU-ARSENE, PhD

ISSN 0014-8237 (for the Printed Edition)
ISSN 2065-0019 (for the On -Line Edition)



"Printech" Publishing House
Bucharest-Romania

IN VITRO ESTROGENIC/ANTI-ESTROGENIC EFFECTS OF CERTAIN FOOD ADDITIVES AND COSMETIC PRESERVATIVES

ANCA POP¹, BELA KISS^{1*}, TUDOR DRUGAN², JULIEN CHERFAN¹, FELICIA LOGHIN¹

¹*“Iuliu Hațieganu” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Toxicology, Cluj-Napoca, Romania*

²*“Iuliu Hațieganu” University of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Informatics and Biostatistics, Cluj-Napoca, Romania*

** corresponding author: kbela@umfcluj.ro; kissbela@gmail.com*

Abstract

In the present study we evaluated the estrogenic/anti-estrogenic effects of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG) and butyl paraben (BP), compounds extensively used as antioxidants/conservatives in food, food packaging, cosmetics and pharmaceuticals, using the luciferase assay. BP and PG were found out to have dual effect. BHA was discovered to have only anti-estrogenic effects, while BHT was the only compound tested in the present studies that did not have any effect.

Rezumat

În prezentul studiu s-au evaluat efectele estrogenice/anti-estrogenice ale butilhidroxianisolului (BHA), butilhidroxitoluenului (BHT), propil galatului (PG) și ale butil parabenului (BP) compuși folosiți ca antioxidanți sau conservanți în industria alimentară, a ambalajelor, cosmeticelor, produselor farmaceutice, folosind testul luciferazei. BP și PG au prezentat efecte duale. BHA s-a dovedit a avea doar efect anti-estrogenic, în timp ce BHT a fost singurul compus testat care nu a prezentat niciun efect.

Keywords: BHA, BHT, PG, PB, luciferase assay.

Introduction

In recent years, concern has been expressed regarding the possible endocrine disrupting effects of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate (PG) and butyl paraben (BP). Several *in vitro* assays have been performed to evaluate the potential of these antioxidants and preservatives to mimic or interfere with the effects of sex hormones.

Butylated hydroxyanisole (BHA) was considered to be a weak estrogenic compound, while butylated hydroxytoluene (BHT) was discovered to be less estrogenic than its' "chemical cousin", BHA, but was

also included on a list of nonestrogenic chemicals by other research groups [1, 6, 9, 12, 13, 14].

While for BHA and BHT there is a dilemma whether they are estrogenic, for propyl gallate (PG) the results are even more interesting, some studies suggesting that PG is an estrogenic compound, while others are presenting PG as an antagonist on the estrogen receptors [1, 13].

If the above three compounds generated controversy, when parabens were studied, they were reported as having estrogenic activity, the estrogenic potency increasing with the side-alkyl chain [4, 5, 8, 10, 11].

For analysing these *in vitro* estrogenic effects, different tests were developed: competitive ligand-ligand, cell proliferation, yeast two-hybrid and reporter gene assay.

The aim of this study was to characterize the potential estrogenic and/or anti-estrogenic effect of BHA, BHT, PG and butyl paraben (BP) using the luciferase assay, an assay that involves the compound binding to the estrogen receptor, ER $_{\alpha}$ or ER $_{\beta}$, followed by receptor-ligand dimerization, translocation to the nucleus, binding to estrogen-response-elements (ERE) in the DNA and transactivation of gene expression. The present work is a preliminary step in evaluating the endocrine disruptive effect of binary mixtures of 17- β -estradiol and the four tested compounds.

Materials and Methods

Chemicals and Reagents

BHA, BHT, PG, BP and 17 β -estradiol (E $_2$, $\geq 98\%$) were purchased from Sigma Aldrich (Steinheim, Germany). All four compounds of interest were prepared as 1000 μ L stock solutions in dimethyl sulfoxide (DMSO, $\geq 99.5\%$, Riedel-de Haën, Seelze, Germany) at 510 mM, 500 mM, 1000 mM and 512 mM, respectively.

Stock solutions were subsequently diluted with DMSO to obtain serial concentrations of 0, 0.15, 0.5, 1.5, 5, 15, 30, 50, 150 and 300 mM for all four chemicals in aliquot volumes of 500 μ L. These serial dilutions were then used to obtain the desired test concentration range for individual compounds.

E $_2$ was prepared as 1210 μ L stock solution in DMSO at 100 mM, 1 mM and 10000 nM. Stock solutions were subsequently diluted with DMSO to obtain serial concentrations of 0, 0.005, 0.015, 0.05, 0.15, 0.5, 1.5, 5, 15, 50, 150, 300, 500, 1500, 5000 nM, in aliquot volumes of 500 μ L. These serial dilutions were then used to obtain the desired test concentrations for the assays.

Resazurin, tricine, ethylenediamines tetraacetic acid (EDTA), dithiothreitol (DTT), and adenosine triphosphate (ATP) were purchased

from Sigma Aldrich. $(\text{MgCO}_3)_4\text{Mg}(\text{OH})_2 \cdot 5\text{H}_2\text{O}$ was obtained from Acros Organics (Geel, Belgium), 1,2-diaminocyclohexane- $\text{N},\text{N},\text{N}',\text{N}'$ -tetraacetic acid (CDTA) and Tris were from Fluka (Buchs, Switzerland) and luciferin ($\geq 99\%$) was from Roth (Karlsruhe, Germany). All solvents and reagents were of analytical grade. RPMI1640 + GlutaMAX culture medium, trypsin and charcoal stripped fetal barrier serum (FBS) were purchased from Gibco (Paisley, UK). Dulbecco's Modified Eagle's Medium F-12 (DMEM F-12) was purchased from Sigma Aldrich. Fetal Bovine Serum (FBS) was obtained from Sigma (Steinheim, Germany) and Dulbecco's Phosphate Buffered Saline (PBS) was obtained from Invitrogen.

Cell cultures

T47D-KBluc human breast cancer cells (estrogen receptor (ER_α and ER_β) positive) were obtained from the American Type Culture Collection (ATCC, USA). The cells were maintained in 75 cm^3 plastic flasks with RPMI1640 + GlutaMAX medium, supplemented with 10% FBS at 37°C in an atmosphere of 5% CO_2 , under saturating humidity. Dulbecco's Phosphate Buffered Saline was used to rinse the cells and trypsin was used to detach cells from plastics. Phenol red-free Dulbecco's Modified Eagle's Medium F-12 (DMEM F-12), containing 10% charcoal stripped FBS was used during the experiments.

Viability assay

Viability was assessed using a resazurin-based assay. The cells were seeded at 5×10^5 cells/mL (96 wells/plate) in RPMI1640+GlutaMAX medium. Following a 24 h incubation at 37°C, 5% CO_2 , the cells were rinsed with 200 μL PBS and then exposed to individual test compounds in increasing concentrations and mixtures compound-estradiol for 24 h. The experiments were performed in triplicate and included 2 controls in each plate (cells exposed only to culture medium and cells exposed to culture medium containing 0.2% DMSO) and blanks without cells containing 200 μL of a 100 μM resazurin solution in culture medium. Cell viability was evaluated by measuring the capacity of the cells to reduce resazurin, a non-fluorescent reagent, to resorufin, a fluorescent product. The cells were rinsed with 200 μL PBS and then incubated for 3 h at 37°C, 5% CO_2 in the presence of a 200 μL resazurin solution 100 μM . The fluorescence was measured at $\lambda_{\text{excitation}}=530/25$; $\lambda_{\text{emission}}=590/35$, using a plate-reader (Synergy 2 Multi-Mode Microplate Reader, BioTek) and cell viability was expressed as a percentage of non-treated controls.

All experiments were repeated three times and in each plate the exposure for each concentration was done in triplicate.

Luciferase assay

The cells were seeded at 8×10^5 cells/mL (96 wells/plate) in DMEM F-12. After a 24 h incubation at 37°C, 5% CO₂, the cells were rinsed with 200 µL PBS and then exposed for 24 h to individual test compounds in increasing concentrations or binary mixtures of 30 pM E₂ and compounds. The assays for estrogenic activity included a positive control (E₂, 30 pM) and two negative controls (assay medium and assay medium with 0.2% DMSO respectively). The assays for anti-estrogenic activity included a positive control (E₂, 30 pM), two negative controls (assay medium and assay medium with 0.2% DMSO) and followed the same protocol, except that the cells were exposed to binary mixtures of E₂ (30 pM) and BHA, BHT, PG or BP in increasing concentrations. After exposure to test chemicals, the cells were rinsed with 200 µL $\frac{1}{2}$ PBS. Low salt buffer containing 10 mM Tris, 1.99 mM DTT and 2 mM EDTA was added at a volume of 30 µL per well. Following a 15-minute incubation at -20°C, the plates were frozen at -80°C for a minimum of 30 minutes to lyse the cells. Plates were thawed on ice and shaken for 30 minutes at room temperature. Luciferase activity was measured in 96-well plates in a luminometer (Synergy 2 Multi-Mode Microplate Reader, BioTek) with automatic injection of 100 µL luciferin FlashMix [0.47mM luciferin, 20 mM tricine, 1.07 mM (MgCO₃)₄Mg(OH)₂.5H₂O, 0.1 mM EDTA, 2 mM DTT and 5 mM ATP, pH 7.8] in each well. Light emission was extinguished with 50 µL NaOH 0.2 M to stop the reaction.

Data analysis and statistics

Relative luminescence units (RLUs) were corrected by subtracting the mean response of control wells. To compare data, the maximum induction of luciferase, obtained at 30 pM E₂, was set as 100%. Data were expressed as mean percentages of the maximal signal observed for 30 pM estradiol.

To calculate the half-maximal efficient concentrations (EC₅₀ for estrogenic effect) and half-maximal inhibitory concentrations (IC₅₀ for anti-estrogenic effect) we used the four parameter Hill function. Graphing of the dose-response curves and nonlinear curve-fitting were carried out using SigmaPlot 12 software. The results were expressed in mean $\pm$ standard deviation (S.D.).

Results and Discussion

The range of concentrations at which the compounds were tested for endocrine disrupting effects are comparable to the ones reported in other *in vitro* assays [3, 4, 7, 9].

Cell viability after exposure to individual compounds

The solvent used during the experiments, namely DMSO 0.2% (v/v), did not induce any significant cytotoxicity.

There was no statistically significant decrease in the luminescence intensity in the case of cell exposure to BHT, PG and BP for concentrations between 0.3 – 100 μM . These results indicate that these compounds are not cytotoxic in concentrations between 0.3 and 100 μM . For BHA the tests were performed for concentration up to 200 μM .

Cell viability after exposure to a mixture of compound - estradiol (compound at increasing concentrations + E2 at 30 pM)

When analysing the viability data for mixtures compound-estradiol, it was noticed that none of them presented significant toxicity when compared to control.

A first observation regarding the viability is that when the toxicity of compound-estradiol (30 pM) mixture was tested, the E₂ turned out to protect the cells from the toxic effect of high concentrations of compounds. This cytoprotective effect was suggested in other research papers [2].

Estrogenic effect (individual exposure)

The cells were exposed for 24 hrs at BHA, BHT, PG and BP in the concentrations selected based on the viability data. Where it was possible, the EC₅₀ value was calculated.

PG exhibited an estrogenic effect at concentrations of 30, 60 and 100 μM . Maximum effect was found at 30 μM and it represented 43.0% from E₂ max, while at 60 μM the signal was calculated to represent 37.9% from E₂ max. At 100 μM , the signal decreased at 23.7% from E₂ max. The cellular viability at 100 μM did not indicate any cytotoxicity; therefore the decreased signal is not a result of a toxic effect. In case of PG, only EC₂₅ was calculated, EC₂₅ = 2.57 μM .

BHA did not present any significant difference when compared to the data obtained in the wells where the cells were exposed to medium with DMSO.

The same way as with BHA, BHT also was found not to have estrogenic properties, while BP presented itself as an estrogenic compound with an EC₅₀ value of 3.09 μM .

For BP, the maximum response was observed at 10 μM (124.4% from E₂ max) as seen in Figure 1.




Figure 1.
Relative luciferase activity in case of exposure to BP

Anti-estrogenic effect

All four compounds were tested for anti-estrogenic properties. BHA, PG and BP were found to inhibit estradiol's activity, while BHT had no significant effect.

For BHA, PG and BP, the IC_{50} was calculated (BHA - IC_{50} = 170.91 μ M, PG - IC_{50} = 45.03 μ M, BP - IC_{50} = 59.82 μ M). The potential of the selected compounds to decrease the luciferase induction produced by E_2 is presented in Figure 2-4.






Figure 2.
Relative luciferase activity in case of exposure to BP + E_2

**Figure 3.**

Relative luciferase activity in case of exposure to PG + E₂

**Figure 4.**

Relative luciferase activity in case of exposure to BHA + E₂

BHA was reported in literature to have an estrogenic effect (when it was tested on U2-OS ER_α and ER_β and MCF-7 cell lines), but the present study using the same range of concentrations found no estrogenic activity for BHA [9, 12, 13].

Lowest effect concentration for BHA in ER_α in ter Veld et. Al, was 5.9 μM and 8.4 μM in ER_β, but the maximal effect obtained was not higher than 19%, (18.3% in case of ER_α, 15.6% in case of ER_β) [13]. Also, the mixture BHA + E₂ was not found to have an additive effect, contrary to the results reported by ter Veld et al [13]. The IC₅₀ calculated in the present study was higher than the concentrations tested by the above research group; this could explain the fact that the anti-estrogenic effect was not observed by ter Veld et al. Okubo et Kano in a relative binding affinity assay found BHA capable of competing for the ER_α and ER_β with E₂, showing IC₅₀ values of 200 μM (for ER_α) and 900 μM (for ER_β) [9]. Our results on the

T47DK-Bluc cell line (expressing both ER receptors) sustain the anti-estrogenic activity with an IC_{50} of 170.91 μ M.

BHT is the only compound tested in the present studies that did not have any effect. None of the concentrations used were able to give any signal when investigating the estrogenic effect, or significantly inhibit E_2 at 30pM. Wada et al. described BHT as an estrogenic compound using also a reporter gene assay (transfected embryonic kidney fibroblast 293T cell line), where an important luciferase activity (significant when compared to control) appeared at 50 μ M and over. They observed a statistically significant effect compared to control, but only slightly above 20% from E_2 max [14]. This concentration was included in our study, but our results did not confirm this kind of effect for BHT under the assay conditions. The results from the present study sustain the conclusion of Okubo and Kano, that BHT is a non-estrogenic compound [9].

In our study, PG exhibited an estrogenic effect but it represented only 43.0% (at 30 μ M) from the maximum induction showed by E_2 . Also, when analysing the anti-estrogenic effect, the IC_{50} value of PG was calculated to be 45.03 μ M. So, in the same range of concentrations, PG could act as an agonist-antagonist; if alone, it could bind to the estrogen receptor and activate the gene expression, while in the presence of a more potent estrogen (E_2 in the present study) it might just block the estrogen receptors. Also, a second theory could be speculated. Due to the higher concentrations of PG in the tested mixtures (when compared to E_2), it could bind to more estrogen receptors than E_2 . However, given its' lower transactivation potency compared to E_2 , the measured signal would not be as significant as in the case of estradiol. E_2 has less receptors available, so the total signal E_2 +PG would be smaller when compared to the signal induced by E_2 alone. The *in vitro* studies published by Adamasi et al. showed that PG is one of the strongest ligands among the xenochemicals that are known as ER α binders (at 54 nM), but without inducing any transactivation activity at the concentrations tested, suggesting that PG is a pure antagonist [1].

The present study supports the anti-estrogenic effect of PG, but the concentration needed to inhibit the E_2 effect (at 30 pM) is in the micromolar range, which means that for a concentration of 10^{-10} M E_2 it was needed a concentration of PG around 10^{-5} M. Even if the findings of Adamasi et al support the mentioned effect, their results (transactivation and binding studies) indicate PG as a more potent antagonist than it was found in our study, using T47DKB-luc cell line. According to Adamasi et al. the

estrogenic effect of 10^{-8} - 10^{-7} M E_2 observed in a transactivation study was inhibited by a tenfold higher concentration of PG [1].

PG was also found by ter Veld et al. to have estrogenic effects in both ER_α and ER_β expressing cells; the potency in ER_α was found to be 109% from E_2 max, while in ER_β the potency was calculated to represent 60% from E_2 max [13]. Contrary to our results, ter Veld et al found the mixture PG and E_2 to be additive.

BP registered a maximal effect at 10 μ M (124.4% from E_2 max) in the present research. This concentration gave also the maximal effect in the cell proliferation assay [4]. Above this concentration, there is still an estrogenic effect, but it decreases in intensity. As this cell line is not free of other endogenous steroid receptors, this should be considered when trying to explain the fact that the maximum response from BP is higher compared to E_2 max. Besides this, the superagonism could be explained by the BP potential modulation of the activity of several kinases involved in ERE (estrogen response elements) activation, but for this mechanism molecular studies are needed, this being beyond the scope of this study [13].

Even if the latest reviews described parabens as compounds that gave full agonist response in whole cells at lower concentrations, our data show that in the same range of concentrations, BP can act either as agonist or antagonist [3]. To our knowledge, the anti-estrogenic effect of BP was not reported so far in the literature using the luciferase assay.

Conclusions

Most of the *in vitro* evaluations of the endocrine disruptive potential of the selected compounds reported in the literature involve proliferation, ligand binding or luciferase induction assays on MCF-7, respectively U2-OS cell lines. The present work offers additional information obtained on a different *in vitro* system, the T47DK-Bluc cell line, the reporter gene induction being recognised to reflect more accurately the interaction with the estrogen receptors.

BP was found to have an estrogenic effect, but also an anti-estrogenic effect at a concentration 6 times higher than the one that gave the maximal effect as an estrogen.

BHA was found to have only anti-estrogenic effects, while PG was discovered to have a dual effect.

The present results highlight the need for precaution regarding the population exposure to the selected compounds due to their potential negative impact on the endocrine system.

The impact of differences between the regulatory requirements included in the biowaiver guidance for *in vitro* testing on the dissolution profiles of mycophenolate mofetil has been evaluated, using several immediate release oral solid dosage forms containing mycophenolate mofetil. The experimental data indicated that the conclusion of similarity is not influenced by hydrodynamic parameters. The acidic stage didn't reveal any significant difference in release, due to the rapid disintegration of the formulations and to the high solubility of the drug. The acetate buffer media provided the most discriminatory conditions for the differences in the qualitative and quantitative compositions. Specific limitations in comparison of different concentrations in the non-sink media were reported.

Acknowledgements

This work was supported by a grant of the Romanian National Authority for Scientific Research, CNCS – UEFISCDI, project number PN-II-RU-TE-2012-3-0157.

References

1. Amadasi A., Mozzarelli A., Meda C., Maggi A., Cozzini P., Identification of xenoestrogens in food additives by an integrated *in silico* and *in vitro* approach. *Chem. Res. Toxicol.*, 2009; 22: 52-63.
2. Bishop J., Simpkins J.W., Estradiol treatment increases viability of glioma and neuroblastoma cells *in vitro*. *Mol. Cell. Neurosci.*, 1994; 5(4): 303-308.
3. Boberg J., Taxvig C., Christiansen S., Hass U., Possible endocrine disrupting effects of parabens and their metabolites. *Reprod. Toxicol.*, 2010; 30: 301-312.
4. Byford J.R., Shaw L.E., Drew M.G.B., Pope G.S., Sauer M.J., Darbre P.D., Oestrogenic activity of parabens in MCF-7 human breast cancer cells. *J. Steroid. Biochem.*, 2002; 80: 49-60.
5. Darbre P.D., Harvey P.W., Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. *J. Appl. Toxicol.*, 2008; 28: 561-578.
6. Jobling S., Reynolds T., White R., Parker M.G., Sumpter J.P., A variety of environmentally persistent chemicals, including some phthalate plasticizer, are weakly estrogenic. *Environ. Health Perspect.*, 1995; 103(6): 582-587.
7. Lee S.H., Kim S.J., Park J.R., Jo E.H., Ahn N.S., Park J.S., Oestrogenic activity of parabens *in vitro* estrogen assays. *J. Food Hyg. Safety.*, 2006; 21(2): 100-106.
8. Duca A., Manda G., Mihele D., The cytotoxic potential effect of some flavoring agents on a mouse fibroblast cell culture. *Farmacia*, 2012; 60(1): 58-63.
9. Okubo T., Kano I., Studies on estrogenic activities of food additives with human breast cancer MCF-7 cells and mechanism of estrogenicity by BHA and OPP. *Yakugaku Zasshi.*, 2003; 123(6): 443-452.
10. Okubo T., Yokoyama Y., Kano K., Kano I., ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer cells MCF-7 cells and expression of ER α and PR. *Food Chem. Toxicol.*, 2001; 39: 1225-1232.
11. Routledge E.J., Parker J., Odum J., Ashby J., Sumpter J.P., Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic. *Toxicol. Appl. Pharmacol.*, 1998; 153(1): 12-19.
12. Soto A.M., Sonnenschein C., Chung K.L., Fernandez M.F., Olea N., Serrano F.M., The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. *Environ. Health Persp.*, 1995; 103(7): 113-122.

13. ter Veld M.G.R., Schouten B., Louisse J., van Es D.S., van der Saag Rietjens I.M.C.M., Murk A.J., Estrogenic potency of food-packaging-associated plasticizers and antioxidants as detected in ER α and ER β reporter gene cell lines. *J. Agric. Food Chem.*, 2006; 54: 4407-4416.
14. Wada H., Tarumi H., Imazato S., Narimatsu M., Ebisu S., *In vitro* estrogenicity of resin composites. *J. Dent. Res.*, 2004; 83(3): 222-226.

Manuscript received: February 2014